Term ends no later than Sep 3, 2040 · Low confidence
20-year base term ends Sep 3, 2040
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Create Medicines, Inc.
Filed May 5, 2023 as application 18/313,126 · Granted Apr 14, 2026
Base term, 20 years from filing
Today
2020
2040
Clock starts
Sep 3, 2020
Sep 3, 2020
Ends no later than
Sep 3, 2040
Sep 3, 2040
Granted
Apr 14, 2026
Apr 14, 2026
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 0 of 3 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 3, 2020, when application PCT/US2020/049240, the earliest non-provisional in its chain, was filed (this one was filed May 5, 2023); a parent in its chain could not be resolved (the next row) | Sep 3, 2040 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Sep 3, 2040 | Low confidence |
This family
| US 11,672,874 | In force no later than Sep 2040 | no later than Sep 2040 |
| US 12,766,198 | In force Jul 2043 | Jul 2043 |
| Application 17/855,423 | Abandoned not computed | not computed |
| Application 17/855,230 | Abandoned not computed | not computed |
| US 12,599,678 | this patent no later than Sep 2040 | no later than Sep 2040 |
| Application 18/313,087 | Pending not computed | not computed |
6 of 7 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 16, 2023 Reel 64609, frame 76 | Getts, Daniel; Wang, Yuxiao; Bisaria, Namita; Scherbakova, Inna; Ly, Socheata | Myeloid Therapeutics, Inc. | Assignment of Assignor's Interest |
| Aug 16, 2023 Reel 64614, frame 127 | Shcherbakova, Inna | Myeloid Therapeutics, Inc. | Confirmatory |
| Oct 15, 2025 Reel 73098, frame 11 | Myeloid Therapeutics, Inc. | Create Medicines, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Sep 2040
Term ends no later than Sep 3, 2040. Maintenance fees still fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Sep 3, 2040. We will not guess the cap.
Citations
We have no citation count for this patent yet. That is not the same as never having been cited.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.